DM did one of those faux interviews and was "asked" about it by in 2015:  Its on StreetWise Reports:

TLSR: How do pediatric orphan diseases fit into your strategy?

DM: The FDA may issue expedited coupons to companies pursuing pediatric programs in orphan indications to speed clinical trials and FDA reviews. These coupons are marketable and have sold for between $70M and $160M. We probably would monetize it, if we get one.

https://www.streetwisereports.com/pub/na/disrupting-treatment-of-cardiovascular-disease-with-epigenetics-resverlogix-ceo-donald-mccaffrey